Montelukast Ametas (Montelukast Sodium)

Montelukast selectively antagonizes the cysteinyl leukotriene receptor CysLT1, inhibiting the action of leukotriene D4. This blocks leukotriene‑driven bronchoconstriction, mucus secretion and inflammatory cell recruitment, leading to improved airway function and reduced allergic inflammation.

The specific dose of Montelukast Ametas is determined by the prescribing healthcare professional based on the patient’s age, weight, severity of disease and clinical response. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for Montelukast in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy or breastfeeding should discuss treatment options with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with allergic components or exercise‑induced symptoms, whereas inhaled steroids target broader airway inflammation. Choice of therapy depends on individual disease profile and physician assessment.

Montelukast Ametas should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain stability and potency throughout its shelf life.

Montelukast Ametas is taken orally, typically as a tablet swallowed whole with water. It can be taken with or without food, according to the prescriber’s instructions. Consistent daily dosing helps maintain steady drug levels for optimal therapeutic effect.

Serious adverse events, although rare, include severe skin reactions such as Stevens‑Johnson syndrome, angioedema, eosinophilic granulomatosis with polyangiitis, hepatic injury and neuropsychiatric effects like mood changes or suicidal thoughts. Patients should seek immediate medical attention if any of these symptoms develop.

Montelukast Ametas is contraindicated in individuals with known hypersensitivity to montelukast or any of its excipients. Caution is advised for patients with severe liver disease, active psychiatric disorders, or those taking interacting medications that could alter its efficacy or safety profile.